reviewed april 2026|next review october 2026|88 physicians psi has verified|3024 published studies
Melanocyte-Stimulating Hormone (α-MSH)
Alpha-melanocyte-stimulating hormone (alpha-MSH) is a 13-amino-acid naturally occurring (the body's own) peptide derived from proopiomelanocortin (POMC) processing that serves as the parent molecule for the entire melanocortin drug class, activating five melanocortin receptors (MC1R-MC5R) and serving as the pharmacological basis for three FDA-approved drugs: setmelanotide (Imcivree, genetic obesity), bremelanotide (Vyleesi, HSDD), and afamelanotide (Scenesse, EPP).
Evidence landscape: 3024 published studies
Published studies indexed under this compound. The broader melanocortin literature exceeds 10,000 papers spanning pharmacology, dermatology, endocrinology, and immunology.
- 55 Human
- 113 Animal
- 32 Reviews
- 2824 Other research
Native alpha-MSH is not FDA-approved (too short-lived for therapeutic use). Three analogs derived from its pharmacology are FDA-approved: setmelanotide (Imcivree, 2020, MC4R agonist for genetic obesity), bremelanotide (Vyleesi, 2019, MC4R agonist for HSDD), and afamelanotide (Scenesse, 2019, MC1R agonist for EPP).
Native alpha-MSH has a half-life under 5 minutes, preventing direct therapeutic use. FDA-approved analogs are prescription medications. Unregulated melanocortin analogs (melanotan I/II) sold online carry significant safety risks.
The melanocortin system is one of the most therapeutically productive peptide signaling pathways in medicine. Alpha-MSH is the naturally occurring (the body's own) ligand that identified the target biology. Five receptor subtypes with distinct tissue distributions enable targeted drug development: MC1R for pigmentation, MC4R for appetite, MC3R/MC1R for inflammation.
PSI Assessment
Three FDA-approved drugs trace their pharmacology directly to alpha-MSH, making the melanocortin system one of the most therapeutically productive peptide signaling pathways in medicine. Setmelanotide targets MC4R to treat rare genetic obesity. Bremelanotide targets MC4R to treat hypoactive sexual desire disorder. Afamelanotide targets MC1R to protect against light sensitivity in erythropoietic protoporphyria. All three were designed by modifying the 13-amino-acid alpha-MSH structure to achieve longer duration, receptor selectivity, and clinical utility that the native peptide's sub-5-minute half-life prevents.
Parent molecule of three FDA-approved drugs. The melanocortin system spans pigmentation, appetite, sexual function, and inflammation. Native peptide half-life under 5 minutes.
The mechanism is melanocortin receptor activation across five subtypes. MC1R on melanocytes drives pigmentation through cAMP/PKA-mediated melanogenesis. MC4R in the hypothalamus suppresses appetite through POMC neuron activation. MC1R and MC3R on immune cells suppress NF-kB signaling to reduce inflammation. MC5R on exocrine glands modulates sebaceous secretion. The receptor diversity explains how one 13-amino-acid peptide influences biology as different as skin color, body weight, sexual desire, and immune response.
What the evidence supports
The melanocortin system is one of the most therapeutically validated peptide signaling pathways in clinical medicine. Three FDA-approved drugs (setmelanotide for genetic obesity, bremelanotide for HSDD, afamelanotide for EPP) trace their pharmacology to alpha-MSH's receptor interactions. MC4R is a validated target for appetite suppression. MC1R activation stimulates melanogenesis and provides photoprotection. Anti-inflammatory effects through NF-kB suppression are documented across multiple cell types.
What is not yet established
Selective agonists for individual melanocortin receptor subtypes without cross-reactivity. Long-term cardiovascular safety of chronic MC4R activation. Broader anti-inflammatory applications through MC3R modulation. Whether the anti-inflammatory potential of the melanocortin pathway can be exploited therapeutically beyond the current approved indications.
Research Evidence
The findings below cover the receptor pharmacology, the FDA-approved therapeutic applications, and the anti-inflammatory potential that remains under investigation.
Evidence by condition
Evidence dimensions across alpha-MSH research areas. Pigmentation and obesity applications have FDA-approved drugs. Anti-inflammatory and skin biology applications are characterized in animal studies.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Pigmentation | ||||
| Obesity/MC4R | ||||
| Anti-Inflammatory | ||||
| Skin Biology |
The melanocortin receptor family (MC1R-MC5R) was cloned and characterized by Mountjoy et al. (1992), establishing the molecular basis for the entire therapeutic class. Each receptor subtype has distinct tissue distribution and biological function.
This receptor identification enabled the rational drug design that produced all three FDA-approved melanocortin drugs. Without knowing the receptor subtypes, targeted drug development would not have been possible.
Setmelanotide (MC4R agonist) produced substantial and sustained weight loss in patients with genetic obesity caused by leptin receptor deficiency. This validated MC4R as a therapeutic target for appetite suppression in defined patient populations.
The approval is for specific genetic obesity conditions (POMC, PCSK1, LEPR deficiency), not general obesity. Whether MC4R agonism can be applied more broadly depends on managing side effects including sexual arousal (MC4R cross-reactivity) and skin hyperpigmentation (MC1R cross-reactivity).
Alpha-MSH suppresses NF-kB signaling and reduces pro-inflammatory cytokine production (TNF-alpha, IL-6, IL-1beta) across multiple immune cell types. The anti-inflammatory pathway is mediated primarily through MC1R and MC3R.
The anti-inflammatory potential is well characterized in laboratory and animal studies but has not been developed into a therapeutic application. The KPV (Lys-Pro-Val) fragment (the C-terminal tripeptide of alpha-MSH) retains anti-inflammatory activity and is explored independently.
55 Human|113 Animal|32 Reviews
View all 3024 indexed studiesHow Melanocyte-Stimulating Hormone (α-MSH) Works
Alpha-MSH activates five different receptors throughout the body, each controlling a different function. MC1R controls skin color. MC4R controls appetite. MC1R and MC3R calm inflammation. The fact that one small peptide can influence such different biological processes explains why three different FDA-approved drugs were built from its template, each targeting a different receptor for a different condition.
Alpha-MSH is the parent molecule for the entire melanocortin drug class. It activates five melanocortin receptors (MC1R through MC5R), each responsible for different biological functions: MC1R controls skin pigmentation, MC4R controls appetite, and MC1R/MC3R modulate inflammation. Three FDA-approved drugs (setmelanotide, bremelanotide, afamelanotide) trace their pharmacology directly back to this 13-amino-acid peptide.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Alpha-MSH (Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2) is a 13-amino-acid peptide derived from POMC cleavage. It activates MC1R (melanocytes, immune cells; Gs/cAMP/PKA; melanogenesis, anti-inflammation), MC3R (CNS, peripheral tissues; energy homeostasis, immune modulation), MC4R (hypothalamus; Gs/cAMP; appetite suppression), and MC5R (exocrine glands; sebaceous secretion). The core pharmacophore His-Phe-Arg-Trp is shared across all therapeutic analogs. Native half-life is less than 5 minutes due to rapid enzymatic degradation.
What is Melanocyte-Stimulating Hormone (α-MSH) being studied for?
Researchers are studying Melanocyte-Stimulating Hormone (α-MSH) across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Melanocyte-Stimulating Hormone (α-MSH) overall. This means a compound can have human studies for one condition but only animal data for another.
Pigmentation
·Human TrialsMC1R activation stimulates melanogenesis. Afamelanotide (Scenesse), an alpha-MSH analog, is FDA-approved for erythropoietic protoporphyria (EPP). The melanocortin pigmentation pathway is one of the best-characterized receptor-mediated responses in dermatology.
Limitations: Unregulated melanocortin peptides (melanotan) marketed for tanning carry significant risks including cardiovascular effects and promotion of melanocytic nevi. Native alpha-MSH is too short-lived for therapeutic use.
Obesity/MC4R
·FDA ApprovedSetmelanotide (Imcivree) is FDA-approved for genetic obesity caused by POMC, PCSK1, or LEPR deficiency. MC4R is a validated appetite-suppression target.
Limitations: Approval is limited to specific genetic obesity conditions. Broader obesity applications face challenges with side effect management (sexual arousal, hyperpigmentation from receptor cross-reactivity).
Anti-Inflammatory
·Animal StudiesAlpha-MSH suppresses NF-kB signaling and reduces pro-inflammatory cytokines through MC1R and MC3R in animal models (animal research). The anti-inflammatory pathway is well characterized but not yet developed into a therapeutic.
Limitations: No anti-inflammatory melanocortin drug has been developed. The KPV fragment is explored independently for gut inflammation.
Skin Biology
·Animal StudiesMC1R activation provides UV photoprotection through DNA repair pathway activation, independent of melanin production. Loss-of-function MC1R variants are associated with increased skin cancer risk.
Limitations: Photoprotective applications beyond EPP are investigational. The relationship between MC1R variants and skin cancer risk is observational.
Safety and Regulatory Status
FDA Status: Native alpha-MSH is not used therapeutically. Three analogs are FDA-approved: setmelanotide (Imcivree), bremelanotide (Vyleesi), afamelanotide (Scenesse). Each has its own safety profile from clinical development.
Availability: Native alpha-MSH has a half-life under 5 minutes. FDA-approved analogs are prescription medications. Unregulated melanocortin analogs (melanotan I/II) sold online are not FDA-approved and carry significant safety risks.
Class context: Naturally occurring (the body's own) peptide. The approved analogs have well-characterized safety profiles. Common class effects include injection site reactions, nausea, and skin hyperpigmentation. Unregulated melanotan products carry additional cardiovascular, nevi promotion, and quality control risks.
Alpha-MSH is naturally occurring (the body's own) with no safety concerns from normal physiology. The FDA-approved analogs have well-characterized safety profiles. The primary safety concern in the melanocortin space is unregulated melanotan products marketed online for tanning, which carry cardiovascular risks and may promote melanocytic nevi.
Questions and Comparisons
Questions the evidence raises for a Melanocyte-Stimulating Hormone (α-MSH) discussion.
Comparison and Related Research
Alpha-MSH is compared with its therapeutic analogs and the KPV fragment that retains selective anti-inflammatory activity.
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Cloned and characterized the melanocortin receptor family (MC1R through MC5R), establishing the molecular basis for melanocortin signaling. This foundational work revealed five receptor subtypes with distinct tissue distributions and functions spanning pigmentation, appetite, inflammation, and sexual behavior.Mountjoy KG et al., 1992 in Science. View on PubMed
- 2.Comprehensive review of alpha-MSH's anti-inflammatory effects across multiple organ systems. The paper documented how melanocortin peptides suppress NF-kB signaling, reduce pro-inflammatory cytokine production, and modulate immune cell function, establishing the melanocortin system as a major endogenous anti-inflammatory pathway.Catania A et al., 2004 in Pharmacol Rev. View on PubMed
- 3.Clinical trial demonstrating that setmelanotide (an MC4R agonist derived from alpha-MSH pharmacology) produced substantial and sustained weight loss in patients with genetic obesity caused by leptin receptor deficiency. This study validated the melanocortin pathway as a therapeutic target for severe genetic obesity.Clement K et al., 2018 in Nat Med. View on PubMed
- 4.Pivotal Phase III trial data for bremelanotide (another melanocortin receptor agonist based on alpha-MSH pharmacology), demonstrating significant improvement in sexual desire and reduction in distress in premenopausal women with hypoactive sexual desire disorder. This led to FDA approval of bremelanotide (Vyleesi) in 2019.Kingsberg SA et al., 2019 in Obstet Gynecol. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.